Drug policy bill repeals unnamed provision—effect unclear without source text

What it does

This bill repeals a specific provision (section 704(b)(12)) of the 1998 Office of National Drug Control Policy Reauthorization Act. Without access to the text of that provision, the civic effect cannot be determined from this bill alone — the repeal could remove a restriction, eliminate a mandate, or strike a definition. The bill's title suggests an intent toward evidence-based drug policy, but the operative mechanism is a single-line repeal of an unnamed provision.

Why we flagged it

The bill is a single-sentence repeal of a named but unquoted provision. Its functional character cannot be determined without reading section 704(b)(12) of the 1998 Act. The title suggests drug-policy reform, but the operative text is a bare citation.

What the text implies

• The bill's title ('Evidence-Based Drug Policy Act') frames the repeal as progressive reform, but the actual target provision is not disclosed in this text — readers cannot verify whether the repeal advances or undermines evidence-based policy without consulting the 1998 Act.
• Repealing a provision without stating its current effect or rationale for removal is a transparency gap that invites suspicion of either concealment or legislative carelessness.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The civic impact depends entirely on what section 704(b)(12) currently does. If it mandates a harmful policy or blocks evidence-based reform, repeal is a net benefit; if it protects public health or enforces accountability, repeal is a net cost. The bill provides no text or summary of the target provision.

Named in the bill

Office of National Drug Control Policy (ONDCP), Office of National Drug Control Policy Reauthorization Act of 1998

Where it stands

2 cosponsors: 2 Democrats.

• Apr 29, 2025 — Introduced · Congress.gov: “Introduced in House”
• Apr 29, 2025 — Referred to House Committee on the Judiciary and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Oversight and Government Reform, and in addition to the Committees on Energy and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $30,000 in lobbying spend. A filing names 11 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Dina Titus, the sponsor, reported $827,196 in PAC receipts in the 2026 cycle.

• Students for Sensible Drug Policy — $30,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.